What not to mix with tadalafil is a critical safety question for anyone prescribed this phosphodiesterase type 5 (PDE5) inhibitor for erectile dysfunction or benign prostatic hyperplasia. Tadalafil works by increasing blood flow through smooth muscle relaxation, but when combined with certain medications—particularly nitrates, alpha-blockers, or drugs affecting the CYP3A4 enzyme—it can cause dangerous drops in blood pressure or other serious adverse effects. Understanding these interactions is essential for safe use. This article provides evidence-based guidance aligned with UK clinical practice, MHRA warnings, and BNF recommendations to help patients and healthcare professionals identify which substances must be avoided or used with caution alongside tadalafil.

What Not to Mix with Tadalafil: Key Drug Interactions

Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor licensed in the UK for the treatment of erectile dysfunction and benign prostatic hyperplasia. It works by inhibiting PDE5, increasing cGMP levels and relaxing smooth muscle in the corpus cavernosum and vascular tissue, thereby increasing blood flow to specific areas of the body. Whilst tadalafil is generally well-tolerated, it can interact with several medications, foods, and lifestyle factors, potentially leading to serious adverse effects.

Understanding these interactions is essential for patient safety. The most critical concern involves medications that affect blood pressure, as tadalafil itself causes vasodilation. When combined with certain drugs—particularly nitrates or guanylate cyclase stimulators (such as riociguat)—the additive effect can result in severe, potentially life-threatening hypotension. The Medicines and Healthcare products Regulatory Agency (MHRA) and the electronic Medicines Compendium (eMC) provide clear contraindications and warnings regarding these combinations.

Before starting tadalafil, patients should provide their GP or prescriber with a complete medication history, including prescription drugs, over-the-counter medicines, herbal supplements, and recreational substances. This comprehensive review helps identify potential interactions and allows for appropriate dose adjustments or alternative treatments. Pharmacists also play a vital role in counselling patients about safe tadalafil use.

This article examines the key substances that should not be mixed with tadalafil, explaining the mechanisms behind these interactions and providing evidence-based guidance aligned with UK clinical practice. Patients taking tadalafil should never adjust their medication regimen without consulting a healthcare professional, as doing so may compromise both efficacy and safety.

Nitrates and Tadalafil: A Dangerous Combination

The concurrent use of tadalafil with nitrates or nitric oxide donors represents an absolute contraindication—meaning these medications must never be taken together. Nitrates are commonly prescribed for angina (chest pain due to coronary artery disease) and include medications such as glyceryl trinitrate (GTN), isosorbide mononitrate, isosorbide dinitrate, and nicorandil. These may be administered as tablets, sprays, patches, or intravenous preparations.

Both tadalafil and nitrates work through pathways involving nitric oxide and cyclic guanosine monophosphate (cGMP). Nitrates increase nitric oxide levels, whilst tadalafil prevents the breakdown of cGMP. When combined, this dual mechanism produces a profound and potentially fatal drop in blood pressure (severe hypotension). Symptoms may include dizziness, fainting, chest pain, or even myocardial infarction or stroke due to inadequate blood flow to vital organs.

The MHRA explicitly warns against this combination, and the British National Formulary (BNF) lists nitrates as a contraindication to all PDE5 inhibitors. Importantly, the long half-life of tadalafil (approximately 17.5 hours) means that this interaction risk persists well beyond a single dose. For patients who have taken tadalafil as needed, nitrates should not be administered for at least 48 hours after the last dose, and if absolutely required, should only be given under close medical supervision with haemodynamic monitoring. Patients on regular once-daily tadalafil therapy must avoid nitrates entirely.

Recreational drugs such as amyl nitrite ('poppers') also contain nitrates and pose the same serious risk. Patients must be counselled to avoid these substances completely whilst taking tadalafil. In emergency situations where a patient taking tadalafil develops chest pain, they should call 999 or go directly to A&E, and inform paramedics or emergency department staff immediately about tadalafil use, as this will influence treatment decisions. Alternative anti-anginal medications that do not interact with tadalafil may be considered under specialist cardiology guidance.

Blood Pressure Medications and Alpha-Blockers to Avoid

Tadalafil can interact significantly with medications used to manage hypertension and benign prostatic hyperplasia, particularly alpha-adrenergic blockers (alpha-blockers). These drugs—including doxazosin, tamsulosin, alfuzosin, and terazosin—relax smooth muscle in blood vessels and the prostate. When combined with tadalafil, the additive vasodilatory effects may cause symptomatic hypotension, characterised by dizziness, light-headedness, or fainting, especially upon standing (orthostatic hypotension).

According to the tadalafil Summary of Product Characteristics (SmPC), coadministration with doxazosin is not recommended due to the higher risk of significant blood pressure reduction. If both medications are clinically necessary, patients should be established on a stable dose of the alpha-blocker before introducing tadalafil at the lowest effective dose. Tamsulosin 0.4 mg has a lower interaction risk compared to doxazosin. When both medications are prescribed, they should ideally be separated by at least 4 hours to minimise the risk of hypotension. Patients should be advised to rise slowly from sitting or lying positions to minimise orthostatic symptoms.

Other antihypertensive medications—including calcium channel blockers, ACE inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and diuretics—may also have additive blood pressure-lowering effects when combined with tadalafil. Whilst these interactions are generally less pronounced than with alpha-blockers, patients with poorly controlled hypertension or those taking multiple antihypertensive agents should be monitored closely. Blood pressure should be stable before initiating tadalafil, and patients should report any symptoms of hypotension to their GP.

Regular blood pressure monitoring is advisable when starting tadalafil in patients on antihypertensive therapy. Dose adjustments of either medication may be necessary to maintain therapeutic efficacy whilst minimising adverse effects. Patients should never discontinue blood pressure medications without medical supervision, as this may lead to rebound hypertension or cardiovascular complications.

Other Medications That Interact with Tadalafil

Tadalafil is metabolised primarily by the hepatic enzyme CYP3A4, meaning that drugs which inhibit or induce this enzyme can significantly alter tadalafil plasma concentrations. Strong CYP3A4 inhibitors—such as ritonavir, ketoconazole, itraconazole, clarithromycin, erythromycin, and cobicistat—can increase tadalafil levels, potentially leading to enhanced adverse effects including headache, flushing, dyspepsia, and hypotension. When these medications are prescribed concurrently, tadalafil doses should be reduced according to BNF guidance. For erectile dysfunction treated as needed, patients taking potent CYP3A4 inhibitors should not exceed 10 mg of tadalafil in a 72-hour period. For once-daily tadalafil, a reduced dose of 2.5 mg may be considered, though coadministration is generally not recommended.

Conversely, CYP3A4 inducers such as rifampicin, phenytoin, carbamazepine, bosentan, and St John's wort may reduce tadalafil plasma concentrations, potentially diminishing therapeutic efficacy. Patients taking these medications may require dose adjustments or alternative treatments.

Guanylate cyclase stimulators such as riociguat (used for pulmonary hypertension) are absolutely contraindicated with tadalafil. This combination can cause additive hypotensive effects that may be dangerous.

Other PDE5 inhibitors—including sildenafil and vardenafil—should not be taken concurrently with tadalafil, as this increases the risk of adverse effects without providing additional therapeutic benefit. Patients sometimes attempt to combine these medications, but this practice is not supported by evidence and is potentially harmful.

Certain HIV protease inhibitors (particularly ritonavir and saquinavir) are potent CYP3A4 inhibitors and require substantial tadalafil dose reductions. Patients with HIV should discuss erectile dysfunction management with their HIV specialist to ensure safe prescribing. Similarly, patients taking ciclosporin should be monitored, as it may moderately inhibit tadalafil metabolism.

Grapefruit juice inhibits intestinal CYP3A4 and may increase tadalafil absorption. Patients should avoid or limit grapefruit juice consumption while taking tadalafil to prevent unpredictable increases in drug exposure.

Foods, Alcohol and Lifestyle Factors to Consider

Unlike some other PDE5 inhibitors, tadalafil absorption is not significantly affected by food, meaning it can be taken with or without meals. This represents an advantage over sildenafil, whose absorption may be delayed by high-fat foods. However, patients should maintain a balanced diet and avoid excessive fatty meals, which can contribute to cardiovascular risk factors that underlie erectile dysfunction.

Alcohol consumption requires careful consideration when taking tadalafil. Both substances cause vasodilation and can lower blood pressure. Whilst moderate alcohol intake is unlikely to cause significant problems in most patients, excessive drinking increases the risk of symptomatic hypotension, dizziness, and headache. According to the tadalafil SmPC, higher alcohol intake (around 5 units or more) can increase the risk of orthostatic symptoms. The NHS advises limiting alcohol to no more than 14 units per week, spread over several days, and avoiding binge drinking. Heavy drinking may also impair erectile function independently of medication, reducing tadalafil's effectiveness.

Patients should be particularly cautious when first starting tadalafil, as individual responses to the combination of alcohol and medication vary. Symptoms such as light-headedness, palpitations, or fainting after drinking alcohol whilst on tadalafil should prompt medical review. Chronic excessive alcohol consumption can also contribute to erectile dysfunction through multiple mechanisms, including hormonal changes, nerve damage, and cardiovascular disease.

Recreational drug use, particularly cocaine and amphetamines, poses serious risks when combined with tadalafil. These stimulants affect cardiovascular function and may increase the risk of myocardial infarction, stroke, or dangerous arrhythmias. As mentioned previously, nitrate-containing recreational drugs ('poppers') are absolutely contraindicated. Patients should be counselled about these risks in a non-judgemental manner, with emphasis on harm reduction and patient safety.

Lifestyle modifications can enhance tadalafil efficacy and reduce interaction risks. These include smoking cessation (smoking damages blood vessels and impairs erectile function), regular physical activity, weight management, and stress reduction. Patients with underlying cardiovascular disease, diabetes, or other chronic conditions should ensure these are optimally managed, as this improves both general health and sexual function. If symptoms such as chest pain, severe dizziness, prolonged erection (priapism lasting over four hours), or sudden vision or hearing changes occur, patients should call 999 or go directly to A&E. Patients are encouraged to report any suspected side effects via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk).

Frequently Asked Questions